GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VBI Vaccines Inc (OTCPK:VBIVQ) » Definitions » Interest Coverage

VBIVQ (VBI Vaccines) Interest Coverage : 0 (At Loss) (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is VBI Vaccines Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. VBI Vaccines's Operating Income for the three months ended in Mar. 2024 was $-11.75 Mil. VBI Vaccines's Interest Expense for the three months ended in Mar. 2024 was $-2.01 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for VBI Vaccines's Interest Coverage or its related term are showing as below:


VBIVQ's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 119.89
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


VBI Vaccines Interest Coverage Historical Data

The historical data trend for VBI Vaccines's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

VBI Vaccines Interest Coverage Chart

VBI Vaccines Annual Data
Trend Mar14 Mar15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

VBI Vaccines Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of VBI Vaccines's Interest Coverage

For the Biotechnology subindustry, VBI Vaccines's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VBI Vaccines's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VBI Vaccines's Interest Coverage distribution charts can be found below:

* The bar in red indicates where VBI Vaccines's Interest Coverage falls into.


;
;

VBI Vaccines Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

VBI Vaccines's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, VBI Vaccines's Interest Expense was $-8.06 Mil. Its Operating Income was $-55.31 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.30 Mil.

VBI Vaccines did not have earnings to cover the interest expense.

VBI Vaccines's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Here, for the three months ended in Mar. 2024, VBI Vaccines's Interest Expense was $-2.01 Mil. Its Operating Income was $-11.75 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.14 Mil.

VBI Vaccines did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


VBI Vaccines  (OTCPK:VBIVQ) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


VBI Vaccines Interest Coverage Related Terms

Thank you for viewing the detailed overview of VBI Vaccines's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


VBI Vaccines Business Description

Traded in Other Exchanges
N/A
Address
160 Second Street, Floor 3, Cambridge, MA, USA, 02142
VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Executives
Steven Gillis director 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Vaughn B Himes director C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Robert Dillman officer: Chief Commercial Officer C/O VBI VACCINES INC., 160 SECOND STREET, FLOOR 3, CAMBRIDGE MA 02142
Nell Beattie officer: Director, Corp Development/IR 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Linda Bain director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Damian Braga director 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Francisco Diaz-mitoma officer: Chief Medical Officer 222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Christopher Mcnulty officer: CFO and Head of BD C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeff Baxter director, officer: President and CEO C/O VBI VACCINES INC.,, 222 THIRD STREET, STE 2241, CAMBRIDGE MA 02142
Joanne Cordeiro director 171 SWANTON STREET, UNIT 48, WINCHESTER MA 01890
Blaine H. Mckee director C/O HART, 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
Tomer Kariv director C/O ARNO THERAPEUTICS, INC., 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003